Cephalon closes $250 million acquisition of Ception

04/6/2010 | American City Business Journals

Cephalon finalized its purchase of Ception Therapeutics for $250 million, allowing the former to operate the latter as a wholly owned unit. The acquisition provides Cephalon access to Cinquil, Ception's drug candidate for eosinophilic asthma, said Cephalon Chairman and CEO Frank Baldino Jr.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL